PubMed:9669632 JSON TXT

Annnotations TAB JSON ListView MergeView

bc5cdr-valid-experiment

bc5cdr-valid-deepseek-nr-ng

{"project":"bc5cdr-valid-deepseek-nr-ng","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T5","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T6","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T7","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T8","span":{"begin":853,"end":862},"obj":"Chemical"},{"id":"T9","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T10","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T11","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T12","span":{"begin":1487,"end":1490},"obj":"Disease"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gemini-nr-ng

{"project":"bc5cdr-valid-gemini-nr-ng","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":194,"end":204},"obj":"Disease"},{"id":"T6","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T7","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T8","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":484,"end":508},"obj":"Disease"},{"id":"T10","span":{"begin":518,"end":539},"obj":"Disease"},{"id":"T11","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T12","span":{"begin":677,"end":684},"obj":"Chemical"},{"id":"T13","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T14","span":{"begin":853,"end":862},"obj":"Chemical"},{"id":"T15","span":{"begin":1002,"end":1009},"obj":"Chemical"},{"id":"T16","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T17","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T18","span":{"begin":1303,"end":1310},"obj":"Chemical"},{"id":"T19","span":{"begin":1388,"end":1395},"obj":"Chemical"},{"id":"T20","span":{"begin":1462,"end":1474},"obj":"Disease"},{"id":"T21","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T22","span":{"begin":1812,"end":1833},"obj":"Disease"},{"id":"T23","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T24","span":{"begin":2012,"end":2021},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gemini-r-ng

bc5cdr-valid-gemini-nr-g

{"project":"bc5cdr-valid-gemini-nr-g","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":194,"end":204},"obj":"Disease"},{"id":"T6","span":{"begin":227,"end":263},"obj":"Disease"},{"id":"T7","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T8","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T9","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T10","span":{"begin":484,"end":496},"obj":"Disease"},{"id":"T11","span":{"begin":518,"end":527},"obj":"Disease"},{"id":"T12","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T13","span":{"begin":708,"end":717},"obj":"Disease"},{"id":"T14","span":{"begin":820,"end":829},"obj":"Disease"},{"id":"T15","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T16","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T17","span":{"begin":1462,"end":1474},"obj":"Disease"},{"id":"T18","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T19","span":{"begin":1652,"end":1661},"obj":"Chemical"},{"id":"T20","span":{"begin":1695,"end":1698},"obj":"Disease"},{"id":"T21","span":{"begin":1812,"end":1821},"obj":"Disease"},{"id":"T22","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T23","span":{"begin":2012,"end":2021},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid

bc5cdr-valid-gemini-r-g

{"project":"bc5cdr-valid-gemini-r-g","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":227,"end":263},"obj":"Disease"},{"id":"T6","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T7","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T8","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":484,"end":508},"obj":"Disease"},{"id":"T10","span":{"begin":518,"end":539},"obj":"Disease"},{"id":"T11","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T12","span":{"begin":708,"end":729},"obj":"Disease"},{"id":"T13","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T14","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T15","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T16","span":{"begin":1462,"end":1486},"obj":"Disease"},{"id":"T17","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T18","span":{"begin":1812,"end":1833},"obj":"Disease"},{"id":"T19","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T20","span":{"begin":2012,"end":2021},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gpt-nr-ng

{"project":"bc5cdr-valid-gpt-nr-ng","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gpt-r-ng

{"project":"bc5cdr-valid-gpt-r-ng","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T6","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T7","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T8","span":{"begin":484,"end":496},"obj":"Disease"},{"id":"T9","span":{"begin":518,"end":527},"obj":"Disease"},{"id":"T10","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T11","span":{"begin":708,"end":717},"obj":"Disease"},{"id":"T12","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T13","span":{"begin":871,"end":880},"obj":"Disease"},{"id":"T14","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T15","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T16","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T17","span":{"begin":1462,"end":1474},"obj":"Disease"},{"id":"T18","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T19","span":{"begin":1625,"end":1637},"obj":"Disease"},{"id":"T20","span":{"begin":1652,"end":1661},"obj":"Chemical"},{"id":"T21","span":{"begin":1695,"end":1698},"obj":"Disease"},{"id":"T22","span":{"begin":1746,"end":1755},"obj":"Chemical"},{"id":"T23","span":{"begin":1812,"end":1821},"obj":"Disease"},{"id":"T24","span":{"begin":1834,"end":1837},"obj":"Disease"},{"id":"T25","span":{"begin":1877,"end":1886},"obj":"Chemical"},{"id":"T26","span":{"begin":1934,"end":1943},"obj":"Chemical"},{"id":"T27","span":{"begin":2012,"end":2021},"obj":"Chemical"},{"id":"T28","span":{"begin":2087,"end":2090},"obj":"Disease"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gpt-r-g

{"project":"bc5cdr-valid-gpt-r-g","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T6","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T7","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T8","span":{"begin":484,"end":496},"obj":"Disease"},{"id":"T9","span":{"begin":518,"end":527},"obj":"Disease"},{"id":"T10","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T11","span":{"begin":708,"end":717},"obj":"Disease"},{"id":"T12","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T13","span":{"begin":871,"end":880},"obj":"Disease"},{"id":"T14","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T15","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T16","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T17","span":{"begin":1462,"end":1474},"obj":"Disease"},{"id":"T18","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T19","span":{"begin":1625,"end":1637},"obj":"Disease"},{"id":"T20","span":{"begin":1652,"end":1661},"obj":"Chemical"},{"id":"T21","span":{"begin":1695,"end":1698},"obj":"Disease"},{"id":"T22","span":{"begin":1746,"end":1755},"obj":"Chemical"},{"id":"T23","span":{"begin":1812,"end":1821},"obj":"Disease"},{"id":"T24","span":{"begin":1834,"end":1837},"obj":"Disease"},{"id":"T25","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T26","span":{"begin":1877,"end":1886},"obj":"Chemical"},{"id":"T27","span":{"begin":1934,"end":1943},"obj":"Chemical"},{"id":"T28","span":{"begin":2012,"end":2021},"obj":"Chemical"},{"id":"T29","span":{"begin":2087,"end":2090},"obj":"Disease"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gpt-nr-g

{"project":"bc5cdr-valid-gpt-nr-g","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T3","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T4","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T5","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T6","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T7","span":{"begin":484,"end":508},"obj":"Disease"},{"id":"T8","span":{"begin":518,"end":539},"obj":"Disease"},{"id":"T9","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T10","span":{"begin":708,"end":729},"obj":"Disease"},{"id":"T11","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T12","span":{"begin":871,"end":892},"obj":"Disease"},{"id":"T13","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T14","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T15","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T16","span":{"begin":1462,"end":1486},"obj":"Disease"},{"id":"T17","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T18","span":{"begin":1625,"end":1637},"obj":"Disease"},{"id":"T19","span":{"begin":1670,"end":1694},"obj":"Disease"},{"id":"T20","span":{"begin":1746,"end":1755},"obj":"Chemical"},{"id":"T21","span":{"begin":1812,"end":1833},"obj":"Disease"},{"id":"T22","span":{"begin":1834,"end":1837},"obj":"Disease"},{"id":"T23","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T24","span":{"begin":1877,"end":1886},"obj":"Chemical"},{"id":"T25","span":{"begin":1934,"end":1943},"obj":"Chemical"},{"id":"T26","span":{"begin":2012,"end":2021},"obj":"Chemical"},{"id":"T27","span":{"begin":2087,"end":2090},"obj":"Disease"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-deepseek-r-ng

{"project":"bc5cdr-valid-deepseek-r-ng","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T5","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T6","span":{"begin":484,"end":508},"obj":"Disease"},{"id":"T7","span":{"begin":518,"end":539},"obj":"Disease"},{"id":"T8","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T9","span":{"begin":1462,"end":1490},"obj":"Disease"},{"id":"T10","span":{"begin":2012,"end":2021},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gemini-r-m

{"project":"bc5cdr-valid-gemini-r-m","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T6","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T7","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T8","span":{"begin":484,"end":496},"obj":"Disease"},{"id":"T9","span":{"begin":518,"end":527},"obj":"Disease"},{"id":"T10","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T11","span":{"begin":708,"end":717},"obj":"Disease"},{"id":"T12","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T13","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T14","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T15","span":{"begin":1462,"end":1474},"obj":"Disease"},{"id":"T16","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T17","span":{"begin":1652,"end":1661},"obj":"Chemical"},{"id":"T18","span":{"begin":1695,"end":1698},"obj":"Disease"},{"id":"T19","span":{"begin":1812,"end":1821},"obj":"Disease"},{"id":"T20","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T21","span":{"begin":2012,"end":2021},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gpt-r-m2

{"project":"bc5cdr-valid-gpt-r-m2","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":227,"end":263},"obj":"Disease"},{"id":"T6","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T7","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T8","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T10","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T11","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T12","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T13","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T14","span":{"begin":1487,"end":1490},"obj":"Disease"},{"id":"T15","span":{"begin":1625,"end":1637},"obj":"Disease"},{"id":"T16","span":{"begin":1652,"end":1661},"obj":"Chemical"},{"id":"T17","span":{"begin":1695,"end":1698},"obj":"Disease"},{"id":"T18","span":{"begin":1746,"end":1755},"obj":"Chemical"},{"id":"T19","span":{"begin":1834,"end":1837},"obj":"Disease"},{"id":"T20","span":{"begin":1860,"end":1864},"obj":"Disease"},{"id":"T21","span":{"begin":1877,"end":1886},"obj":"Chemical"},{"id":"T22","span":{"begin":1934,"end":1943},"obj":"Chemical"},{"id":"T23","span":{"begin":2012,"end":2021},"obj":"Chemical"},{"id":"T24","span":{"begin":2087,"end":2090},"obj":"Disease"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-deepseek-r-g

{"project":"bc5cdr-valid-deepseek-r-g","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T6","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T7","span":{"begin":479,"end":482},"obj":"Disease"},{"id":"T8","span":{"begin":484,"end":508},"obj":"Disease"},{"id":"T9","span":{"begin":518,"end":539},"obj":"Disease"},{"id":"T10","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T11","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T12","span":{"begin":853,"end":862},"obj":"Chemical"},{"id":"T13","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T14","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T15","span":{"begin":1877,"end":1894},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-deepseek-nr-g

{"project":"bc5cdr-valid-deepseek-nr-g","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T6","span":{"begin":411,"end":435},"obj":"Disease"},{"id":"T7","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T8","span":{"begin":484,"end":508},"obj":"Disease"},{"id":"T9","span":{"begin":518,"end":539},"obj":"Disease"},{"id":"T10","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T11","span":{"begin":820,"end":829},"obj":"Chemical"},{"id":"T12","span":{"begin":853,"end":862},"obj":"Chemical"},{"id":"T13","span":{"begin":985,"end":994},"obj":"Chemical"},{"id":"T14","span":{"begin":1132,"end":1141},"obj":"Chemical"},{"id":"T15","span":{"begin":1286,"end":1295},"obj":"Chemical"},{"id":"T16","span":{"begin":1652,"end":1661},"obj":"Chemical"},{"id":"T17","span":{"begin":1746,"end":1755},"obj":"Chemical"},{"id":"T18","span":{"begin":1877,"end":1886},"obj":"Chemical"},{"id":"T19","span":{"begin":1934,"end":1943},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-deepseek-r-m

{"project":"bc5cdr-valid-deepseek-r-m","denotations":[{"id":"T1","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":129,"end":153},"obj":"Disease"},{"id":"T4","span":{"begin":175,"end":189},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":356},"obj":"Chemical"},{"id":"T6","span":{"begin":437,"end":440},"obj":"Disease"},{"id":"T7","span":{"begin":479,"end":482},"obj":"Disease"},{"id":"T8","span":{"begin":484,"end":496},"obj":"Disease"},{"id":"T9","span":{"begin":518,"end":527},"obj":"Disease"},{"id":"T10","span":{"begin":631,"end":640},"obj":"Chemical"},{"id":"T11","span":{"begin":2012,"end":2021},"obj":"Chemical"}],"text":"Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\nBACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility. Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).\nMETHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].\nRESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups. In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P \u003c 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P \u003c 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P \u003c 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo. No significant differences in jejunal motility were found in the constipation-predominant IBS group. Symptoms were assessed by using a visual analogue scale before and after treatment. Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 62 +/- 19 mm]. Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P \u003c 0.05); pretreatment, 67 +/- 19 mm].\nCONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS."}

bc5cdr-valid-gpt-r-m